Evidence map›Paper›PMID 38970381›Full record

ArticleRheumatology (Oxford, England)2025

Impact of conventional and biological disease-modifying anti-rheumatic drugs on arterial lesions in Takayasu arteritis.

Diego Bletry, Louis Meyblum, Kristell Desseaux, Mathieu Vautier, Laurent Chiche, Alexandre Le Joncour, Alban Redheuil, Charles Roux, Patrice Cacoub, Julien Gaudric and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Rheumatology (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Management of Takayasu Arteritis - A 2026 Update.Current rheumatology reports · 2026
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Diego BletryDepartment of Internal Medicine and Clinical Immunology, Centre de Référence des Maladies Auto-Immunes Systémiques Rares, Centre de Référence des Maladies Auto-Inflammatoires et de l'Amylose inflammatoire (CEREMAIA), Sorbonne Universités, Paris, France; INSERM, UMR_S 959, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.ORCID 0009-0009-2496-6989
Louis MeyblumDepartment of Interventional Radiology, Sorbonne Universités, Pitié-Salpêtrière University Hospital, Paris, France.
Kristell DesseauxDepartment of Biostatistics and Medical Information, AP-HP Saint-Louis University Hospital, ECSTRRA Team, CRESS UMR 1153, INSERM, University of Paris, Paris, France.
Mathieu VautierDepartment of Internal Medicine and Clinical Immunology, Centre de Référence des Maladies Auto-Immunes Systémiques Rares, Centre de Référence des Maladies Auto-Inflammatoires et de l'Amylose inflammatoire (CEREMAIA), Sorbonne Universités, Paris, France; INSERM, UMR_S 959, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.
Laurent ChicheDepartment of Vascular Surgery, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.
Alexandre Le JoncourDepartment of Internal Medicine and Clinical Immunology, Centre de Référence des Maladies Auto-Immunes Systémiques Rares, Centre de Référence des Maladies Auto-Inflammatoires et de l'Amylose inflammatoire (CEREMAIA), Sorbonne Universités, Paris, France; INSERM, UMR_S 959, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.
Alban RedheuilDepartment of Cardiovascular Imaging, Sorbonne Universités, Pitié-Salpêtrière University Hospital, Paris, France.
Charles RouxDepartment of Interventional Radiology, Sorbonne Universités, Pitié-Salpêtrière University Hospital, Paris, France.
Patrice CacoubDepartment of Internal Medicine and Clinical Immunology, Centre de Référence des Maladies Auto-Immunes Systémiques Rares, Centre de Référence des Maladies Auto-Inflammatoires et de l'Amylose inflammatoire (CEREMAIA), Sorbonne Universités, Paris, France; INSERM, UMR_S 959, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.
Julien GaudricDepartment of Vascular Surgery, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.
Lucie BiardDepartment of Biostatistics and Medical Information, AP-HP Saint-Louis University Hospital, ECSTRRA Team, CRESS UMR 1153, INSERM, University of Paris, Paris, France.
David SaadounDepartment of Internal Medicine and Clinical Immunology, Centre de Référence des Maladies Auto-Immunes Systémiques Rares, Centre de Référence des Maladies Auto-Inflammatoires et de l'Amylose inflammatoire (CEREMAIA), Sorbonne Universités, Paris, France; INSERM, UMR_S 959, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe definition of Takayasu arteritis (TAK) remission and disease activity is still unclear. Vascular imaging is an essential tool for following-up patients. Herein, we aimed to compare the evolution of vascular lesions (i.e. vessel wall thickening and stenosis) under conventional cDMARDs relatively to biological DMARDs (bDMARDs) in TAK patients followed with the same CT angiography modalities.

methodWe compared 75 lines of therapy in TAK patients who received cDMARDs (n = 40 lines) and bDMARDs (n = 35 lines) using CT angiography. We established 1-3 main target vessels with vessel wall thickening and/or stenosis. Every targeted vessel had its thickness and its lumen diameter measured at the initiation of immunosuppressive treatment and at 12 months.

resultsWe observed an overall reduction in arterial wall thickness in 73% of cases and 31% had >25% relative decrease in the wall thickness. Using a linear mixed effects model, first-line immunosuppressive therapy (P = 0.012) and bDMARDs relatively to cDMARDs (P = 0.026) were independently associated with vessel wall thickness reduction in TAK. Thirty-eight percent of the stenotic vessels had a > 25% relative increase in lumen diameter under immunosuppressive therapy. The relative increase >25% in lumen diameter was noted in 56% vs 17% with bDMARDs compared with cDMARDs.

conclusionImmunosuppressive treatments can reduce arterial wall thickness and widen lumen diameter in TAK. bDMARDs seem to be more effective than cDMARDs to improve arterial lesions in TAK.

Indexed as

Antirheumatic AgentsImmunosuppressive AgentsTakayasu ArteritisAdultComputed Tomography AngiographyFemaleHumansMaleMiddle AgedRetrospective StudiesYoung AdultAntirheumatic AgentsImmunosuppressive AgentsbiotherapiesimagingTakayasu arteritisvascular lesionsvasculitis

Identifiers

PMID38970381

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.